Seattle: An international team of researchers has identified biological markers in the blood that can help doctors predict who is at high risk of developing active tuberculosis (TB).
One-third of the world’s population is thought to be infected with Mycobacterium tuberculosis (Mtb), the bacterium that causes tuberculosis, but just a small fraction ever develops symptomatic illness.
If validated through additional clinical trials, a test based on these blood biomarkers that the researchers have now identified would allow doctors to target therapies to at-risk people, thus preventing them from getting sick.
The decade-long research effort was led by investigators from the South African Tuberculosis Vaccine Initiative at the University of Cape Town, and the Center for Infectious Disease Research, Seattle, US.
The findings were published in the journal The Lancet.
The biomarkers were identified in two stages. First, researchers collected blood samples for two years from more than 6,000 Mtb-infected but otherwise healthy adolescent volunteers in South Africa.
Analysis of the samples revealed patterns of gene expression that differed between volunteers who eventually developed TB and those who remained healthy.
This risk “signature,” confined to a set of 16 genes, could be detected in a blood sample as early as 18 months before the infected person developed active TB.
Next, the team confirmed the genetic risk signature’s predictive ability in a study of more than 4,500 volunteers in South Africa and The Gambia.
The second study group was more varied in age, health status, ethnicity and exposure to locally common strains of Mtb than volunteers in the first study.
Despite the differences, the same risk signature found in the first study was detected in the people who eventually developed active TB during the second trial. (IANS)
Pregnant women have been systematically overlooked in the development and deployment of new vaccines, undermining their health and their communities’ safety, according to guidelines released this month by an international team of researchers, scientists and health care providers.
The report, developed by the Pregnancy Research Ethics for Vaccines, Epidemics and New Technologies (PREVENT) working group, identifies a cycle of exclusion that prevents pregnant women from accessing the benefits of vaccines.
“There’s a lot of reticence to include pregnant women in research,” said Carleigh Krubiner, the project director and a co-principal investigator for PREVENT.
And that’s led to a shortfall in data about how pregnant women respond to vaccines.
Krubiner, an associate faculty member at the Johns Hopkins Berman Institute of Bioethics, told VOA that researchers and health care providers tend to exclude pregnant women from trials, vaccinations and tracking because they lack evidence of the risks expectant mothers face.
“We continue to have this Catch-22 of not having enough evidence to feel like we can do the research. But if we don’t do the research, we don’t have the evidence,” Krubiner said.
There’s a lot of fear’
Concerns over “theoretical harm” drive decisions to exclude pregnant women from interventions, Krubiner said. But the data scientists do have, often from women not known to be pregnant when they received vaccinations, suggest those concerns are overblown.
In the case of rubella, for example, a contagious viral infection, researchers didn’t find a connection between congenital rubella syndrome and the vaccine when thousands of pregnant women were vaccinated before their pregnancy status was known.
“There’s a lot of fear,” Krubiner said. “And there are certainly biologically plausible risks associated with different types of live replicating viral vaccines.”
Live-virus vaccines contain a weakened version of the disease designed to stimulate an immune response in recipients.
“Very often, the benefits of vaccinating do still outweigh the theoretical, or even real harms that may be posed to the fetus,” Krubiner said.
One vaccine known to cause harm to pregnant women and their fetuses, Krubiner added, is for smallpox. But even in that case, she said, if a threat were imminent, pregnant women should get vaccinated, given the seriousness of the disease. The Centers for Disease Control and Prevention support that guidance.
The advice pregnant women receive about vaccination should reflect what’s known about the particular vaccine and the specific circumstances of the outbreak, Krubiner said.
Recommendations should follow current knowledge about the disease in question, the severity of the threat, and the likelihood of exposure, she added.
But the general guidance is unambiguous.
“At minimum, vaccines should be offered to women, and in many cases they should be strongly recommended,” Krubiner said.
Among those cases is the vaccine for seasonal and pandemic flu, which pregnant women should be urged to receive, in light of the severity of the risks tied to infection — not just for the expectant mother, but the future child as well.
Pregnant women should also be encouraged to receive vaccines for H1N1, also known as swine flu, and DPT, which protects against diphtheria, whooping cough and tetanus.
Involving pregnant women in the benefits of vaccines will require systemic shifts, the PREVENT group said in its report this month.
An important step is to become more proactive in bringing pregnant women into what Krubiner called the “development and research pipeline.” By involving pregnant women early, she said, health care providers aren’t left with the kinds of blind spots about how vaccines will affect expectant mothers and their fetuses that lead to their exclusion.
Even basic information, such as pregnancy status in case reports, sometimes goes untracked, despite being easy to collect and providing insight into the unique burden pregnant women face in disease outbreaks.
More complex data collection will paint a more complete picture. Specific studies could be designed to examine the safety and efficacy of vaccines for pregnant women, for example, or to track effects at different points in gestation.
“Starting anywhere at this point would be better than the dearth of data that we have right now to really try to address the needs of pregnant women and their babies,” Krubiner said.
Disease outbreaks devastate communities. But they also provide opportunities to better prepare for, and respond to, the next epidemic.
In this year’s Ebola outbreaks in Congo, responders have applied lessons from West Africa’s 2014-16 epidemic to community engagement. And drug trials toward the end of the West Africa outbreak produced evidence about the vaccine that’s now being deployed.
But pregnant women weren’t included in those trials, and researchers collected little in the way of data about the burden pregnant women and their offspring face.
“Pregnant women are continuously getting left out of the benefits of scientific advancement in medicine,” Krubiner said.
“If we continue to fail to collect the kinds of data that we need, to generate the kind of evidence that we need and to also have interventions that meet the broader population’s needs,” Krubiner said, “then we’re just going to continue to perpetuate the cycle.” (VOA)